Study of HRS-5041 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
Status:
Recruiting
Trial end date:
2025-08-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety, tolerability and preliminary efficacy of
HRS-5041 in men with progressive metastatic castration resistant prostate cancer. The
objective of this study was to determine the dose-limiting toxicity, maximum tolerance and
recommended dose of HRS-5041 in phase II study.